Loading...

AnaptysBio

Nasdaq:ANAB
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ANAB
Nasdaq
$2B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
ANAB Share Price and Events
7 Day Returns
-8.3%
NasdaqGS:ANAB
-0.6%
US Biotechs
0.5%
US Market
1 Year Returns
-7.5%
NasdaqGS:ANAB
-8.8%
US Biotechs
0.8%
US Market
ANAB Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AnaptysBio (ANAB) -8.3% -1.8% -4.6% -7.5% - -
US Biotechs -0.6% -0.9% -9.1% -8.8% 11.6% 4.7%
US Market 0.5% 0.2% 1.1% 0.8% 37.4% 37.5%
1 Year Return vs Industry and Market
  • ANAB outperformed the Biotechs industry which returned -8.8% over the past year.
  • ANAB underperformed the Market in United States of America which returned 0.8% over the past year.
Price Volatility
ANAB
Industry
5yr Volatility vs Market
Related Companies

ANAB Value

 Is AnaptysBio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AnaptysBio. This is due to cash flow or dividend data being unavailable. The share price is $69.64.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AnaptysBio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AnaptysBio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:ANAB PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.70
NasdaqGS:ANAB Share Price ** NasdaqGS (2019-06-14) in USD $69.64
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,091 Publicly-Listed Companies 17.68x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AnaptysBio.

NasdaqGS:ANAB PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ANAB Share Price ÷ EPS (both in USD)

= 69.64 ÷ -2.70

-25.84x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AnaptysBio is loss making, we can't compare its value to the US Biotechs industry average.
  • AnaptysBio is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does AnaptysBio's expected growth come at a high price?
Raw Data
NasdaqGS:ANAB PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -25.84x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
-14.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 26 Publicly-Listed Biotechs Companies 1.08x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.52x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AnaptysBio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AnaptysBio's assets?
Raw Data
NasdaqGS:ANAB PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $17.34
NasdaqGS:ANAB Share Price * NasdaqGS (2019-06-14) in USD $69.64
United States of America Biotechs Industry PB Ratio Median Figure of 425 Publicly-Listed Biotechs Companies 2.9x
United States of America Market PB Ratio Median Figure of 5,244 Publicly-Listed Companies 1.79x
NasdaqGS:ANAB PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ANAB Share Price ÷ Book Value per Share (both in USD)

= 69.64 ÷ 17.34

4.02x

* Primary Listing of AnaptysBio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AnaptysBio is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess AnaptysBio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AnaptysBio has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ANAB Future Performance

 How is AnaptysBio expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-14.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AnaptysBio expected to grow at an attractive rate?
  • Unable to compare AnaptysBio's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare AnaptysBio's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • AnaptysBio's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:ANAB Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:ANAB Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts -14.3%
NasdaqGS:ANAB Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 86.8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 18%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:ANAB Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:ANAB Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 268 -180 -149 7
2022-12-31 71 -421 -244 7
2021-12-31 10 -208 -199 9
2020-12-31 11 -140 -142 10
2019-12-31 5 -108 -112 9
NasdaqGS:ANAB Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 5 -52 -69
2018-12-31 5 -49 -62
2018-09-30 8 -41 -52
2018-06-30 3 -30 -45
2018-03-31 10 -24 -34
2017-12-31 10 -19 -30
2017-09-30 10 -20 -27
2017-06-30 13 -19 -19
2017-03-31 12 -15 -15
2016-12-31 17 -9 -4
2016-09-30 18 -6 -4
2016-06-30 19 -5 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AnaptysBio is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • AnaptysBio's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:ANAB Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from AnaptysBio Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ANAB Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -5.30 2.40 -12.11 6.00
2022-12-31 -7.90 -3.49 -13.66 6.00
2021-12-31 -6.09 -3.84 -9.47 9.00
2020-12-31 -4.66 -3.59 -5.88 10.00
2019-12-31 -3.88 -2.93 -5.07 10.00
NasdaqGS:ANAB Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.70
2018-12-31 -2.50
2018-09-30 -2.17
2018-06-30 -1.96
2018-03-31 -1.54
2017-12-31 -1.52
2017-09-30 -1.87
2017-06-30 -1.91
2017-03-31 -2.55
2016-12-31 -1.62
2016-09-30 -1.34
2016-06-30 -1.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AnaptysBio will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess AnaptysBio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AnaptysBio has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ANAB Past Performance

  How has AnaptysBio performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AnaptysBio's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AnaptysBio does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AnaptysBio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AnaptysBio's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AnaptysBio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AnaptysBio Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:ANAB Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 5.00 -68.65 15.72
2018-12-31 5.00 -61.66 15.53
2018-09-30 8.00 -51.52 14.33
2018-06-30 3.00 -44.66 12.71
2018-03-31 10.00 -33.72 11.23
2017-12-31 10.00 -30.07 9.34
2017-09-30 9.75 -27.47 7.71
2017-06-30 12.97 -19.49 6.32
2017-03-31 11.82 -14.81 5.12
2016-12-31 16.68 -4.26 4.29
2016-09-30 17.98 -3.51 4.45
2016-06-30 19.31 -3.86 4.33
2016-03-31 18.34 -5.92 4.13
2015-12-31 17.57 -5.41 3.59
2015-09-30 17.22 -1.95 3.09
2015-06-30 18.84 0.23 2.75
2015-03-31 18.15 1.05 2.57
2014-12-31 15.84 0.23 2.35
2013-12-31 5.48 -5.55 1.95

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AnaptysBio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AnaptysBio has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AnaptysBio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AnaptysBio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AnaptysBio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ANAB Health

 How is AnaptysBio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AnaptysBio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AnaptysBio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AnaptysBio's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AnaptysBio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 65x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AnaptysBio Company Filings, last reported 2 months ago.

NasdaqGS:ANAB Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 468.16 8.60 415.67
2018-12-31 486.37 8.20 427.08
2018-09-30 499.68 9.91 493.81
2018-06-30 284.98 11.62 267.91
2018-03-31 294.53 13.33 248.17
2017-12-31 307.58 14.43 248.41
2017-09-30 101.36 14.27 115.72
2017-06-30 109.18 14.11 106.36
2017-03-31 110.12 13.96 103.50
2016-12-31 42.51 13.81 51.23
2016-09-30 44.76 4.98 47.13
2016-06-30 45.56 4.95 50.59
2016-03-31 42.95 4.93 49.32
2015-12-31 43.89 4.90 51.68
2015-09-30 47.38 4.88 55.25
2015-06-30 7.57 4.85 16.89
2015-03-31 6.89 4.82 19.61
2014-12-31 6.56 4.79 22.19
2013-12-31 0.53 0.82 2.81
  • AnaptysBio's level of debt (1.4%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (88.9% vs 1.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AnaptysBio has sufficient cash runway for more than 3 years based on current free cash flow.
  • AnaptysBio has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 66.9% each year.
X
Financial health checks
We assess AnaptysBio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AnaptysBio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ANAB Dividends

 What is AnaptysBio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AnaptysBio dividends. Estimated to be 0% next year.
If you bought $2,000 of AnaptysBio shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AnaptysBio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AnaptysBio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:ANAB Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2011 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:ANAB Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AnaptysBio has not reported any payouts.
  • Unable to verify if AnaptysBio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AnaptysBio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AnaptysBio has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of AnaptysBio's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess AnaptysBio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AnaptysBio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AnaptysBio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ANAB Management

 What is the CEO of AnaptysBio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hamza Suria
COMPENSATION $5,122,232
AGE 42
TENURE AS CEO 7.9 years
CEO Bio

Mr. Hamza Suria, M.Sc., M.B.A. has been the Chief Executive Officer and President of AnaptysBio, Inc., since July 2011. Mr. Suria served as an Acting Chief Executive Officer and Chief Business Officer of AnaptysBio, Inc. He served as Vice President of Corporate Development at Anaptys Biosciences, Inc. since December 2008. He was appointed Vice President of Corporate Development in December 2008. He served as Senior Director of Business Development at Maxygen, where he was responsible for partnering and alliance management of next-generation protein therapeutics with Roche, Sanofi-Aventis, Bayer, Astellas and others. Mr. Suria served as Director of Business Development at Diabetogen Biosciences with responsibility for corporate partnerships with Abgenix and the development of otelixizumab. He held various business development positions at Viron Therapeutics and the Robarts Research Institute. He has been a Director of AnaptysBio, Inc. since July 2011. Mr. Suria holds a BSc in Biochemistry from Kalamazoo College, an MSc in Immunology from the University of Western Ontario and an Executive MBA from the Richard Ivey School of Business. Mr. Suria is an ASAP-certified Alliance Management Professional.

CEO Compensation
  • Hamza's compensation has increased whilst company is loss making.
  • Hamza's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the AnaptysBio management team in years:

2.5
Average Tenure
46
Average Age
  • The tenure for the AnaptysBio management team is about average.
Management Team

Hamza Suria

TITLE
President
COMPENSATION
$5M
AGE
42
TENURE
7.9 yrs

Dominic Piscitelli

TITLE
Chief Financial Officer
COMPENSATION
$2M
AGE
43
TENURE
2.4 yrs

Eric Loumeau

TITLE
General Counsel
COMPENSATION
$2M
AGE
55

Marco Londei

TITLE
Chief Medical Officer
COMPENSATION
$3M
AGE
61
TENURE
2.7 yrs

Hemant Kumar

TITLE
Senior Vice President of Manufacturing

David McKeon

TITLE
VP & Controller
AGE
46
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the AnaptysBio board of directors in years:

4
Average Tenure
64.5
Average Age
  • The tenure for the AnaptysBio board of directors is about average.
Board of Directors

Jamie Topper

TITLE
Chairman
COMPENSATION
$453K
AGE
56

Hamza Suria

TITLE
President
COMPENSATION
$5M
AGE
42
TENURE
7.9 yrs

Hollings Renton

TITLE
Director
COMPENSATION
$451K
AGE
71
TENURE
4 yrs

John Schmid

TITLE
Director
COMPENSATION
$439K
AGE
55
TENURE
4 yrs

Dennis Fenton

TITLE
Director
COMPENSATION
$890K
AGE
66
TENURE
1.3 yrs

Nick Lydon

TITLE
Member of Therapeutic Advisory Board
COMPENSATION
$439K
AGE
61

Jan de Vries

TITLE
Member of Therapeutic Advisory Board
AGE
72

David Lacey

TITLE
Member of Therapeutic Advisory Board
AGE
66
TENURE
7.3 yrs

Mike Gallatin

TITLE
Member of Therapeutic Advisory Board
AGE
64
TENURE
7.3 yrs

Tony Ware

TITLE
Director
COMPENSATION
$445K
AGE
65
TENURE
1.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess AnaptysBio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AnaptysBio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ANAB News

Simply Wall St News

Is AnaptysBio, Inc. (NASDAQ:ANAB) A Financially Strong Company?

See our latest analysis for AnaptysBio ANAB’s Debt (And Cash Flows) Over the past year, ANAB has reduced its debt from US$13m to US$8.6m , which also accounts for long term debt. … Next Steps: Although ANAB’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings. … However, the company will be able to pay all of its upcoming liabilities from its current short-term assets.

Simply Wall St -

Did You Manage To Avoid AnaptysBio's (NASDAQ:ANAB) 42% Share Price Drop?

AnaptysBio isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Shareholders of unprofitable companies usually expect strong revenue growth. … In just one year AnaptysBio saw its revenue fall by 50%.

Simply Wall St -

Is AnaptysBio Inc (NASDAQ:ANAB) As Strong As Its Balance Sheet Indicates?

Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like AnaptysBio Inc (NASDAQ:ANAB), with a market cap of US$2.2b, are often out of the spotlight. … This article will examine ANAB’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … Don’t forget that this is a general and concentrated examination of AnaptysBio's financial health, so you should conduct further analysis.

Simply Wall St -

Market Sentiment Around Loss-Making AnaptysBio Inc (NASDAQ:ANAB)

The company’s loss has recently broadened since it announced a -US$30.07m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$33.72m, moving it further away from breakeven? … The most pressing concern for investors is ANAB’s path to profitability – when will it breakeven

Simply Wall St -

What You Must Know About AnaptysBio Inc's (NASDAQ:ANAB) Financial Health

View our latest analysis for AnaptysBio How does ANAB’s operating cash flow stack up against its debt? … At this current level of debt, ANAB's cash and short-term investments stands at US$248.41M for investing into the business. … Moving onto cash from operations, its small level of operating cash flow means calculating cash-to-debt wouldn't be too useful, though these low levels of cash means that operational efficiency is worth a look.

Simply Wall St -

Why I Sold AnaptysBio Inc (NASDAQ:ANAB)

There's room for improvement on the cash management side of things, but its overall debt level and interest coverage somewhat increases my conviction of the sustainability of the business going forward. … One reason I do like ANAB as a business is its low level of fixed assets on its balance sheet (0.20% of total assets). … A good company is reflected in its financials, and for ANAB, the financials don't look good.

Simply Wall St -

Future Outlook Of The Healthcare Industry And AnaptysBio Inc (ANAB)

The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term. … Healthcare analysts are forecasting for the entire industry, negative growth in the upcoming year , and a massive growth of 44.94% over the next couple of years. … Over the past year, the industry saw growth of 8.45%, though still underperforming the wider US stock market.

Simply Wall St -

ANAB Company Info

Description

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company’s products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.

Details
Name: AnaptysBio, Inc.
ANAB
Exchange: NasdaqGS
Founded: 2005
$1,881,932,209
27,023,725
Website: http://www.anaptysbio.com
Address: AnaptysBio, Inc.
10421 Pacific Center Court,
Suite 200,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ANAB Common Stock Nasdaq Global Select US USD 26. Jan 2017
DB AN6 Common Stock Deutsche Boerse AG DE EUR 26. Jan 2017
LSE 0HFQ Common Stock London Stock Exchange GB USD 26. Jan 2017
Number of employees
Current staff
Staff numbers
78
AnaptysBio employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 01:37
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/06/13
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.